» Articles » PMID: 33808387

MiR-30b-5p Downregulation As a Predictive Biomarker of Coronary In-Stent Restenosis

Overview
Journal Biomedicines
Date 2021 Apr 3
PMID 33808387
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

In-stent restenosis (ISR) is one of the main limitations of percutaneous coronary intervention (PCI) therapy with drug-eluting stents (DES) implantation. The aim of this study was to determine if circulating microRNAs (miRNAs) have diagnostic capability for determining ISR in a cohort of matched patients. Blood samples were collected from 55 patients who underwent previously PCI and were readmitted for a new coronary angiography. Patients were divided into subgroups comprising patients who presented ISR or not (non-ISR). A microarray analysis determined that up to 49 miRNAs were differentially expressed between ISR and non-ISR patients. Of these, 10 miRNAs are related to vascular smooth muscle and endothelial cells proliferation, migration, and differentiation, well-known hallmarks of vascular remodeling. Additionally, we identified that the expression of miR-30b-5p is significantly lower in serum samples of ISR patients, as compared to non-ISR. A further analysis demonstrated that miR-30b-5p provides better values of the receiver operator characteristic curve than other miRNAs and biochemical parameters. Finally, the in-silico analysis suggests that miR-30b-5p is predicted to target 62 genes involved in different signaling pathways involved in vascular remodeling. In conclusion, we determined for the first time that circulating mi-R30b-5p can reliably prognose restenosis in patient with implanted DES, which could be potentially helpful in the establishment of an early diagnosis and therapy of ISR.

Citing Articles

A systematic review and bioinformatic study on clinical, paraclinical, and genetic factors predisposing to stent restenosis following percutaneous coronary intervention.

Shahsanaei F, Gharibzadeh A, Behrooj S, Abbaszadeh S, Nourmohammadi M BMC Cardiovasc Disord. 2024; 24(1):304.

PMID: 38877398 PMC: 11177414. DOI: 10.1186/s12872-024-03955-3.


Cardiac microRNAs: diagnostic and therapeutic potential.

Kablak-Ziembicka A, Badacz R, Okarski M, Wawak M, Przewlocki T, Podolec J Arch Med Sci. 2023; 19(5):1360-1381.

PMID: 37732050 PMC: 10507763. DOI: 10.5114/aoms/169775.


Diabetes and restenosis.

Wilson S, Mone P, Kansakar U, Jankauskas S, Donkor K, Adebayo A Cardiovasc Diabetol. 2022; 21(1):23.

PMID: 35164744 PMC: 8845371. DOI: 10.1186/s12933-022-01460-5.


Differential Expression of miRNA-223 in Coronary In-Stent Restenosis.

Ganjali S, Aghaee-Bakhtiari S, Reiner Z, Sahebkar A J Clin Med. 2022; 11(3).

PMID: 35160300 PMC: 8836934. DOI: 10.3390/jcm11030849.

References
1.
Zhang M, Li F, Wang X, Gong J, Xian Y, Wang G . MiR-145 alleviates Hcy-induced VSMC proliferation, migration, and phenotypic switch through repression of the PI3K/Akt/mTOR pathway. Histochem Cell Biol. 2020; 153(5):357-366. DOI: 10.1007/s00418-020-01847-z. View

2.
Liu Y, Spinelli A, Sun L, Jiang M, Singer D, Ginnan R . MicroRNA-30 inhibits neointimal hyperplasia by targeting Ca(2+)/calmodulin-dependent protein kinase IIδ (CaMKIIδ). Sci Rep. 2016; 6:26166. PMC: 4873751. DOI: 10.1038/srep26166. View

3.
Bradley S, Spertus J, Kennedy K, Nallamothu B, Chan P, Patel M . Patient selection for diagnostic coronary angiography and hospital-level percutaneous coronary intervention appropriateness: insights from the National Cardiovascular Data Registry. JAMA Intern Med. 2014; 174(10):1630-9. PMC: 4276416. DOI: 10.1001/jamainternmed.2014.3904. View

4.
Xu T, Qiu X, Sheng Z, Han Y, Wang J, Tian B . Restoration of microRNA-30b expression alleviates vascular calcification through the mTOR signaling pathway and autophagy. J Cell Physiol. 2019; 234(8):14306-14318. DOI: 10.1002/jcp.28130. View

5.
Smani T, Mayoral-Gonzalez I, Galeano-Otero I, Gallardo-Castillo I, Rosado J, Ordonez A . Non-coding RNAs and Ischemic Cardiovascular Diseases. Adv Exp Med Biol. 2020; 1229:259-271. DOI: 10.1007/978-981-15-1671-9_15. View